Compare, Analyse Cipla with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ACTAVIS (US) - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CIPLA   ACTAVIS
EQUITY SHARE DATA
    CIPLA
Mar-20
ACTAVIS
Dec-18
CIPLA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs58614,247-   
Low Rs3579,557-   
Sales per share (Unadj.) Rs207.03,494.9-  
Earnings per share (Unadj.) Rs18.6-1,125.7-  
Cash flow per share (Unadj.) Rs33.2368.3-  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs195.514,414.7-  
Shares outstanding (eoy) m806.35332.60-   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.33.4 66.8%   
Avg P/E ratio x25.3-10.6 -239.6%  
P/CF ratio (eoy) x14.232.3 44.0%  
Price / Book Value ratio x2.40.8 291.9%  
Dividend payout %21.50-   
Avg Mkt Cap Rs m379,9123,958,701 9.6%   
No. of employees `00025.816.9 152.9%   
Total wages/salary Rs m30,2700-   
Avg. sales/employee Rs Th6,459.668,780.9 9.4%   
Avg. wages/employee Rs Th1,171.20-   
Avg. net profit/employee Rs Th580.2-22,154.4 -2.6%   
INCOME DATA
Net Sales Rs m166,9491,162,397 14.4%  
Other income Rs m3,44222,229 15.5%   
Total revenues Rs m170,3911,184,626 14.4%   
Gross profit Rs m32,06030,461 105.2%  
Depreciation Rs m11,747496,899 2.4%   
Interest Rs m1,97467,077 2.9%   
Profit before tax Rs m21,782-511,287 -4.3%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0130,399 0.0%   
Tax Rs m6,312-6,479 -97.4%   
Profit after tax Rs m14,995-374,409 -4.0%  
Gross profit margin %19.22.6 732.8%  
Effective tax rate %29.01.3 2,286.7%   
Net profit margin %9.0-32.2 -27.9%  
BALANCE SHEET DATA
Current assets Rs m117,038476,754 24.5%   
Current liabilities Rs m43,931421,753 10.4%   
Net working cap to sales %43.84.7 925.5%  
Current ratio x2.71.1 235.7%  
Inventory Days Days9620 488.7%  
Debtors Days Days8566 128.3%  
Net fixed assets Rs m107,424131,577 81.6%   
Share capital Rs m1,6130-   
"Free" reserves Rs m156,0180-   
Net worth Rs m157,6304,794,344 3.3%   
Long term debt Rs m23,6931,688,262 1.4%   
Total assets Rs m236,6267,494,650 3.2%  
Interest coverage x12.0-6.6 -181.8%   
Debt to equity ratio x0.20.4 42.7%  
Sales to assets ratio x0.70.2 454.9%   
Return on assets %7.2-4.1 -174.9%  
Return on equity %9.5-7.8 -121.8%  
Return on capital %12.8-4.8 -265.2%  
Exports to sales %33.00-   
Imports to sales %00-   
Net fx Rs m49,2720-   
CASH FLOW
From Operations Rs m30,685415,281 7.4%  
From Investments Rs m1,040228,143 0.5%  
From Financial Activity Rs m-29,488-712,746 4.1%  
Net Cashflow Rs m2,340-68,977 -3.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 73.63 Rs / USD

Compare CIPLA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare CIPLA With: UNICHEM LAB  STRIDES PHARMA SCIENCE  LUPIN  SUN PHARMA  AJANTA PHARMA  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views On News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Why Did Alembic Pharma Shares Fall Today? (Views On News)

May 5, 2021

Covid-led supply disruptions of API fuel Alembic Pharma's global prospects.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

More Views on News

Most Popular

Time to Buy Smallcaps? (Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners (Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away? (Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her? (Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

FREE Event: Discover Your First Stock for a Potential Rs 7 Crore in Long-term Wealth
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

CIPLA SHARE PRICE


May 7, 2021 (Close)

TRACK CIPLA

MORE ON CIPLA

CIPLA 5-YR ANALYSIS

COMPARE CIPLA WITH

FEATURED VIDEOS

The 'Big' Money is in this 'Small' Detail

Stability, Quality or Green Stocks for 2021?

Market Crash: Picture Abhi Baaki Hai?

It's a Great Time to Buy Gold

More Featured Videos

MARKET STATS